4th February
2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Company")
Board
changes
Venture Life (AIM: VLG), a leader in
developing, manufacturing and commercialising products for the
international self-care market, announces some upcoming
changes to the Board.
The recent acquisition of Health
& Her Limited in November 2024 has increased VLG's presence in
the vitamins and minerals space. Mr Paul McGreevy, Non-Exec Chair
of the Company has identified that as this business segment of VLG
aggressively grows, it presents a potential conflict of interest
with his current position as CEO of Revive Active Limited, an Eire
based vitamins and minerals business, which operates in similar
segments. As a result of this potential future conflict of
interests, and as part of our robust succession plans, Mr McGreevy
has indicated his intention to step down from the Board of VLG as
both Chair and non-executive Director at the time of the
announcement of the Company's annual results for the year ended
31st December 2024, which is expected to be in late
April 2025. Mr Mark Adams, who has been a non-executive director of
the Company since 2022, has accepted the invitation from the Board
to take over as Chair of the Board at that time.
A process has begun to identify and
appoint a replacement non-executive director who will also take the
position of Chair of the Audit Committee, that will be vacated by
Mr Adams when he becomes Chair. A further announcement in
this respect will be made in due course.
The Board wishes to extend its
deepest thanks to Mr McGreevy for all his hard work, insight,
diligence and support of the business since joining us in 2022. His
work as Chair of the Board has facilitated the continued growth of
the business and improvement of its operational efficiency, as well
as of the effectiveness and operation of the Board.
Jerry Randall, CEO of Venture Life Group plc
commented: "I will be very sorry to
lose Paul from the Board as he has been such a positive influence
and support for VLG since he joined, as well as an exceptional
mentor for me. I am sure the Board and everyone at VLG will join me
in thanking Paul for all he has done for us and wishing him well
for his future endeavours"
Paul
McGreevy, Chair of Venture Life Group plc
commented: "My confidence in the
future of VLG has never been higher with so many exciting value
creating initiatives commencing. It saddens me to leave the Board
at this time due to the impending conflict of interests, but I have
absolute confidence in Mark and the rest of the Board to accelerate
our growth. I will be retained as an adviser going forward for
aspects of the business that avoid any conflict of
interests."
For
further information, please contact:
Venture Life Group PLC
|
+44 (0) 1344 578004
|
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
|
|
Cavendish Capital Markets Limited (Nomad and
Broker)
|
+44 (0) 20 7397 8900
|
Stephen Keys / Camilla Hume
(Corporate Finance)
Michael Johnson (Sales)
|
|
|
|
|
|
|
|
|
|
| |
About Venture Life (www.venture-life.com)
Venture Life is an
international consumer self-care company focused on developing,
manufacturing and commercialising products for the global self-care
market. With operations in the UK, Italy, The
Netherlands and Sweden, the Group's product portfolio
includes Balance Activ in the area of women's intimate healthcare,
Earol® supporting ENT care, Lift and Glucogel product ranges for
energy and glucose management and hypoglycaemia, the Health and Her
product range supporting the hormonal lifecycle, Gelclair and Pomi-T for oncology support, the UltraDEX and Dentyl oral care product ranges, products
for fungal infections and proctology, and dermo-cosmetics for
addressing the signs of ageing.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the Company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.